{"id":396630,"date":"2020-08-18T00:00:00","date_gmt":"2020-08-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0028-2020-biopharma-axial-spondyloarthritis-access-reimbursement-us-ankylosing-spondylitis-and-non-radiographic\/"},"modified":"2026-04-14T10:24:26","modified_gmt":"2026-04-14T10:24:26","slug":"acreim0028-2020-biopharma-axial-spondyloarthritis-access-reimbursement-us-ankylosing-spondylitis-and-non-radiographic","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0028-2020-biopharma-axial-spondyloarthritis-access-reimbursement-us-ankylosing-spondylitis-and-non-radiographic\/","title":{"rendered":"Axial Spondyloarthritis | Access &#038; Reimbursement | US | Ankylosing Spondylitis and Non-Radiographic AxSpA | 2020"},"content":{"rendered":"<p>The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-\u03b1) inhibitors (Amgen\u2019s Enbrel, AbbVie\u2019s Humira, Janssen\u2019s Remicade and Simponi \/ Simponi Aria, and UCB\u2019s Cimzia) and two IL-17 inhibitors (Novartis\u2019s Cosentyx and Eli Lilly\u2019s Taltz). The TNF-\u03b1 inhibitors are the most widely prescribed biologics for AxSpA, which is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs), and their positioning as the first-line targeted agents is encouraged through payer policies. To overcome this challenge, the marketers of Cosentyx, Taltz, and emerging therapies, including UCB\u2019s bimekizumab and Pfizer\u2019s Xeljanz, need to understand how best to navigate the access and reimbursement environment, particularly because payers expect to increase their stringency for this indication in the coming years.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the patient-share leaders among AxSpA biologics, and which AxSpA agents do physicians and payers believe perform best on specific clinical and market access factors?<\/li>\n<li>Are there differences in how payers view the different AxSpA subpopulations? What are the biggest reimbursement obstacles that AxSpA drugs face?<\/li>\n<li>What are physicians\u2019 perceptions of the emerging agents bimekizumab and Xeljanz, and how do payers anticipate covering these agents?<\/li>\n<li>What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>U.S. Access &#038; Reimbursement <\/em>provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-396630","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ankylosing-spondylitis","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396630\/revisions"}],"predecessor-version":[{"id":576499,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396630\/revisions\/576499"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=396630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}